SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: mopgcw1/7/2006 6:16:14 AM
  Read Replies (1) of 523
 
Small molecule drug development, both proprietary and partnered with
Pfizer, Merck and Aventis for insomnia, pain, depression/anxiety,
inflammation and obesity/diabetes. Most advanced candidates are
GABA receptor partial agonists, including NG2-73 (wholly owned,
began phase II in Dec. 2005); and NGD 96-3 (partnered with PFE, has
completed phase I testing and was put on hold).

4Q05/1Q06: Phase I data for NG2-73
in insomnia

still patiently holding...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News